0000904454-14-000608.txt : 20140829
0000904454-14-000608.hdr.sgml : 20140829
20140829193127
ACCESSION NUMBER: 0000904454-14-000608
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140827
FILED AS OF DATE: 20140829
DATE AS OF CHANGE: 20140829
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GENOCEA BIOSCIENCES, INC.
CENTRAL INDEX KEY: 0001457612
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 ACORN PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: 617-876-8191
MAIL ADDRESS:
STREET 1: 100 ACORN PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
FORMER COMPANY:
FORMER CONFORMED NAME: GENOCEA BIOSCIENCES INC
DATE OF NAME CHANGE: 20090304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Giannasca Paul
CENTRAL INDEX KEY: 0001591874
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36289
FILM NUMBER: 141076228
MAIL ADDRESS:
STREET 1: CAMBRIDGE DISCOVERY PARK
STREET 2: 100 ACORN PARK DRIVE, 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2014-08-27
0001457612
GENOCEA BIOSCIENCES, INC.
GNCA
0001591874
Giannasca Paul
C/O GENOCEA BIOSCIENCES, INC.
100 ACORN PARK DRIVE, 5TH FLOOR
CAMBRIDGE
MA
02140
0
1
0
0
VP of Development
Common Stock
2014-08-27
4
M
0
1303
2.86
A
1303
D
Common Stock
2014-08-27
4
S
0
1303
12.77
D
0
D
Common Stock
2014-08-28
4
M
0
4602
2.86
A
4602
D
Common Stock
2014-08-28
4
S
0
4602
12.36
D
0
D
Common Stock
2014-08-29
4
M
0
855
2.86
A
855
D
Common Stock
2014-08-29
4
S
0
855
12.86
D
0
D
Stock Option (Right to Buy)
2.86
2014-08-27
4
M
0
1303
0
D
2020-02-17
Common Stock
1303
23012
D
Stock Option (Right to Buy)
2.86
2014-08-28
4
M
0
4602
0
D
2020-02-17
Common Stock
4602
18410
D
Stock Option (Right to Buy)
2.86
2014-08-29
4
M
0
855
0
D
2020-02-17
Common Stock
855
17555
D
The option vested 25% on January 25, 2011 and the remainder vested in equal monthly installments for the next three years thereafter.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.70 to $12.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.48. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.85 to $12.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/Robert E. Farrell, Jr., Attorney-in-fact
2014-08-29